Clinical evaluation of a new alkylating agent, Azetepa, in one hundred and twenty‐five cases of malignant tumors

A new alkylating agent, Azetepa, is described. Our clinical experience in 125 patients with a variety of solid tumors is presented. Azetepa is useful chiefly in the treatment of lymphomas, mammary carcinoma, and carcinomas of the female genital tract. Its effectiveness in carcinomas of the digestive tract and accessory organs is comparable to that of the fluorinated pyrimidines. It can be administered via all conventional routes. Toxicity was very low; no deaths due to hematologic causes occurred. There was no hepato‐renal toxicity. Tentative recommendations are made for dosages and routes of administration.